Can urinary exosomes act as treatment response markers in prostate cancer?

Table 4 Summary of patient's western blot data

			Exosome Markers			Cancer Marker	Prostate Markers
	Patient	Time	CD9	GAPDH	TSG101	5T4	PSMA	PSA	Summary
	LNCap	N/A	++++	+++	+++	+++	++++	++++	The Comparator "Standard" Sample
Good Quality	p8	ADT₄	+++	++	++	++	++	+++	Consistent, High Quality Exosomes.
		ADT₁₂	+++	++	++	++	++	+	Prostate markers diminish with treatment.
		RT₂₀	+++	++	++	+	-	-	5T4 still evident at RT₂₀
	p7	ADT₄	++	+	++	+	+	+	Good quality exosomes, but inconsistent, (increasing with treatment).
		ADT₁₂	++	++	+++	++	+	+	Prostate markers & 5T4 still evident at RT₂₀
		RT₂₀	+++	+++	+++	++	++	++
Intermediate Quality	p1	ADT₄	+	-	-	+	-	+	Inconsistent, (increasing with treatment)
		ADT₁₂	++	-	-	+	-	-	Prostate markers barely detected, no clear pattern.
		RT₂₀	+++	+	++	+	+	-	5T4 still evident at RT₂₀
	p3	ADT₄	+	+	-	+	-	-	Inconsistent, (increasing with treatment)
		ADT₁₂	+	-	++	+	-	-	Prostate markers absent.
		RT₂₀	+++	++	-	++	-	-	Strong 5T4 at RT₂₀
Poor	p9	ADT₄	+++	+	+	+	+	+	Inconsistent, (decreasing with treatment)
		ADT₁₂	++	+	-	-	-	-	Prostate markers barely detected, no clear pattern.
		RT₂₀	+	-	-	-	+	-	No 5T4 at RT₂₀
	p5	ADT₄	-	-	-	-	-	-	Poor quality at 2/3 time-points
		ADT₁₂	-	-	-	-	-	-	Not Evaluable
		RT₂₀	+++	-	++	-	-	-
Very Poor Quality	p10	ADT₄	+++	++	+++	+	+	+	Poor quality at 2/3 time-points
		ADT₁₂	-	-	-	-	-	-	Not Evaluable
		RT₂₀	+	-	-	-	-	-
	p6	ADT₄	+	-	-	-	-	-	Poor quality at 3/3 time-points
		ADT₁₂	++	-	-	-	-	-	Not Evaluable
		RT₂₀	-	-	-	-	-	-

ISSN: 1479-5876